Why Government Health Programs Pay Double for Generic Drugs

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

Why Government Health Programs Pay Double for Generic Drugs

無料で聴く

ポッドキャストの詳細を見る

Episode 30 of The Fiscal Policy Podcast investigates a strange but costly inefficiency: government health programs in the US often pay far more for the exact same generic drugs than private insurers do. Lucas breaks down a 2025 Government Accountability Office report finding that Medicare Part D paid an average of 2.3 times more than commercial plans for 40 common generics in 2023 — costing taxpayers an extra $1.8 billion a year. He explains the structural reasons: opaque pharmacy benefit manager rebates, statutory pricing floors, and a reimbursement formula that was originally designed for brand-name drugs. Luna pushes back on the assumption that government procurement is always wasteful, noting that the VA and Department of Defense negotiate much better prices through a centralized formulary. The episode ends with a real-world reform proposal from the bipartisan Senate Generic Drug Pricing Act, introduced March 2026, which would cap Medicare Part D generic reimbursements at 150% of the national average commercial price. #GenericDrugs #MedicarePartD #GovernmentWaste #DrugPricing #PharmacyBenefitManagers #GAO #SenateGenericDrugPricingAct #FiscalPolicy #TaxpayerDollars #PublicSpending #Economics #LucasAndLuna #FexingoBusiness #BusinessPodcast #HealthEconomics #Procurement #BipartisanReform #Episode30 Keep every episode free: buymeacoffee.com/fexingo

まだレビューはありません